Skadden is representing Covidien plc on tax matters relating to its merger agreement, announced June 1, to acquire all of the outstanding shares of ev3 Inc. for $2.6 billion. Covidien is a global healthcare products company and ev3 develops technologies for the treatment of heart disease.
Covidien Announces Definitive Agreement to Acquire ev3 Inc.
Skadden is representing Covidien plc on tax matters relating to its merger agreement, announced June 1, to acquire all of the outstanding shares of ev3 Inc. for $2.6 billion. Covidien is a global healthcare products company and ev3 develops technologies for the treatment of heart disease.